PPT-Nivolumab + Ipilimumab

vs PlatinumDoublet Chemotherapy as Firstline Treatment for Advanced NonSmall Cell Lung Cancer Initial Results From CheckMate 227 Matthew D Hellmann 1 Tudor Eliade Ciuleanu. Brendan D. Curti, MD. Director, Melanoma Program. Director Biotherapy Program. Providence Cancer Center. Earle A. Chiles Research Institute. Disclaimers. Earle A. Chiles Research Institute accepted grants of. Malignant Melanoma. (8 minutes). Antoni Ribas, M.D., Ph.D.. Professor of Medicine. Professor of Surgery. Professor of Molecular and Medical Pharmacology. Director, Tumor Immunology Program, . Jonsson Comprehensive Cancer Center (JCCC). ipilimumab Intravenous Infusion, 5 mg ipilimumab / mL 10 mL and 40 mL vials Antineoplastic Date of Authorization: September 23, 2015 *TM of Bristol-Myers Squibb Company used under licence by Bristol- the Spectrum of Lung Cancer. Karen Kelly, MD. Professor of Medicine. Associate Director for Clinical Research. Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon. Endowed Chair in Cancer Clinical Research. Amanda Dean, MSN, ACNP-BC, RNFA. Director of Advanced Practice Providers. Banner MD Anderson. Objectives. Recognize and manage mechanism based adverse effects of current targeted agents including: GI distress, dermatologic toxicities, pneumonitis and  anti-angiogenesis  side effects. From Promise to Practice. PRECISION ONCOLOGY IS THE FUTURE OF CANCER CARE.. Tumor genome data informs cancer treatment and clinical pathways, resulting in better health outcomes.. New cancer therapies target the molecular pathways that lead to tumor genesis and progression.. Dr Tan . Jiunn. Liang. Clinical Specialist (Respiratory Medicine). Department of Medicine. Universiti. Malaya Medical Centre. Disclaimer. This program is provided as a service to the medical profession and represents the opinions of the speakers, not necessarily those of Merck or MSD or its affiliates. Program Overview. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Michael A. Postow, MD Assistant Attending Physician Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center New York, New York Removing the Escape Hatch Restoring Immune System Activation and Memory in Cancer proceedings from the live CME event and may include . the use of trade names and other raw, unedited content. . Breakfast with the Investigators . Management of Melanoma. Monday, June 3, 2019 . 6:45 AM – 7:45 AM. actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Consensus OR Controversy? . Clinical Investigators Provide Perspectives on the Treatment of Metastatic Non-Small Cell Lung Cancer in Patients Without Targetable Tumor Mutations . ADULT Updated: October 2 8 , 20 20 eria for Use Page 1 of 3 Regimen Reference Order – CUTA – nivolumab + ipilimumab ARIA: CUTA - [nivolumab + ipilimumab (Phase 1) ] CUTA - [nivolumab q 14 da Lee S. Schwartzberg,. MD, FACP. West Clinic, P.C.; The University of Tennessee. Memphis, Tn.. ICLIO 1. st. Annual National Conference. 10.2.15. Philadelphia, Pa.. Financial Disclosures. I do not currently have any relevant financial relationships to disclose. NSCLC. An update. Solange Peters, MD-PhD. Oncology. . Department. CHUV Lausanne. “In any trial you get the odd patient who does very well, but this is an order of magnitude above that.”. , Mick Peake, .